Relief Therapeutics

Welcome to

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Relief is a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis.

Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

22 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports Half-Year 2022 Results and Provides Corporate Update

15 September 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission

24 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation

22 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

17 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

12 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)

3 August 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

28 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

21 July 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

WE AIM TO PROVIDE RARE DISEASE PATIENTS WITH THERAPIES THAT SIGNIFICANTLY IMPROVE THEIR CONDITION AND QUALITY OF LIFE, ALLOWING THEM TO LIVE THEIR BEST POSSIBLE LIVES AND ACHIEVE THEIR FULL POTENTIAL

Latest News

Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Reports Half-Year 2022 Results and Provides Corporate Update

Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

Company

Pipeline

Investor Relations

News and Events